Leafly (LFLY) FY 2025 Annual General Meeting June 11, 2025 12:00 PM ET Speaker0 Hello, and welcome to Leafly's twenty twenty five Annual Meeting of Stockholders. I'm Jeff Monat, Chairman of the Board of Leafly, and I will serve as Chair of this meeting, which I now call to order. I am joined by Yoko Miyashita, our CEO and secretary and member of the board Peter Lee, our president, COO, and member of the board Andres Manetti, member of the board Suresh Krishnaswamy, our CFO and Allison Pear, our outside coun ...

Financial Data and Key Metrics Changes - The proposal for a reverse stock split has been approved by a majority of votes, indicating a strategic move to potentially enhance the stock price and attract more investors [6] - The adjournment proposal was also approved, allowing for further solicitation of proxies if necessary [6] Business Line Data and Key Metrics Changes - No specific financial data or performance metrics for individual business lines were provided during the meeting [7] Market Data and Key Metrics Changes - There was no detailed market data or key metrics discussed in the meeting [7] Company Strategy and Development Direction - The company is focused on clinical trials and is committed to reporting data as it becomes available, emphasizing transparency in their research process [8] - The management is preparing to draw down NIH grant funding in the foreseeable future, indicating ongoing reliance on external funding sources [9] Management Comments on Operating Environment and Future Outlook - Management has not experienced adverse effects from NIH grant funding cuts to date, but they are cautious about future implications [9] - The company is optimistic about the nature of their grant and the timing, although uncertainties remain [9] Other Important Information - The meeting concluded with a commitment to report clinical trial data as expeditiously as possible, highlighting the importance of quality control and safety review processes [8] Q&A Session Summary Question: How often are clinical trial assessments done during the current clinical study? - Management stated that they report data as soon as it is available, emphasizing the need for quality control and committee checks before publishing results [8] Question: Has your NIH grant funding been affected by the recent funding cuts? - Management confirmed that there have been no adverse effects from NIH grant funding so far, but they are preparing to draw down funds soon, with future implications still uncertain [9]

Sanuwave Health (SNWV) Q4 2024 Earnings Call March 21, 2025 08:30 AM ET Company Participants Morgan Frank - Chairman & CEOPeter Sorensen - CFOChristopher Plahm - Portfolio ManagerIan Cassel - Founder/Cheif Investment Officer Conference Call Participants Carl Byrnes - Managing Director, Senior Research Analyst Operator Good day, everyone, and welcome to today's Samuwave Earnings Call. At this time, all participants are in a listen only mode. Later, you will have the opportunity to ask questions during the qu ...